Azim AKBARZADEH, Mohammadreza MEHRABI, Parisa ESMAEILPOUR, Zahra SAFFARI, Maryam FARAHNAK, Ali FARHANGI, Mohsen CHIANI

4818

Efficacy of pegylated liposomal etoposide nanoparticles on breast cancer cell lines

Efficacy of pegylated liposomal etoposide nanoparticles on breast cancer cell lines

Background/aim: This study aimed to investigate the efficacy of pegylated liposomal etoposide nanoparticles (NPs) against T-47D and MCF-7 breast cancer cell lines. Materials and methods: Pegylated liposomal etoposide NPs were prepared by reverse phase evaporation method. The size, size distribution, and zeta potential of the NPs was measured by a Zetasizer instrument. The cytotoxicity of NPs was inspected by methyl thiazol tetrazolium assay. The release pattern of the drug from the vesicles was studied by the dialysis method. Drug loading and encapsulation efficiency (EE) were also measured. Results: The mean size, size distribution, and zeta potential of pegylated liposomal etoposide NPs were 491 ± 15.5 nm, 0.504 ± 0.14, and 35.8 ± 2.5 mV, respectively. Drug loading and EE were 10.3 ± 1.6% and 99.1 ± 2.8%, respectively. The etoposide release in the formulation was estimated at about 3.48% after 48 h. The cytotoxicity effect of etoposide NPs on T-47D and MCF-7 cell lines of breast cancer showed higher antitumor activity as compared with those of the free drug. Conclusion: Liposome-based NPs may hold great potential as a drug delivery system.
PDF

___

  • 1. Montecucco A, Biamonti G. Cellular response to etoposide treatment. Cancer Lett 2007; 252: 9-18.
  • 2. Ezoe S. Secondary leukemia associated with the anticancer agent, etoposide, a topoisomerase II inhibitor. Int J Environ Res Public Health 2012; 9: 2444-2453.
  • 3. McLeod HL, Evans WE. Clinical pharmacokinetics and pharmacodynamics of epipodophyllotoxins. Cancer Surv 1993; 17: 253-268.
  • 4. Rodman JH, Murry DJ, Madden T, Santana VM. Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation. J Clin Oncol 1994; 12: 2390-2397.
  • 5. Hande KR. Etoposide pharmacology. Semin Oncol 1992; 19 (6 Suppl 13): 3-9.
  • 6. Joel SP, Shah R, Slevin ML. Etoposide dosage and pharmacodynamics. Cancer Chemoth Pharm 1994; 34 (Suppl): S69-S75.
  • 7. Allen TM, Martin FJ. Advantages of liposomal delivery systems for anthracyclines. Semin Oncol 2004; 31(6 Suppl 13): 5-15.
  • 8. Brandl M. Liposomes as drug carriers: a technological approach. Biotechnol Annu Rev 2001; 7: 59-85.
  • 9. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm 2000; 50: 161-177.
  • 10. Rostas J, Dyess DL. Current operative management of breast cancer: an age of smaller resections and bigger cures. Int J Breast Cancer 2012; 2012: Article ID 516417, 7 pages.
  • 11. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
  • 12. Zhang Z, Feng SS. The drug encapsulation efficiency, in vitro drug release, cellular uptake and cytotoxicity of paclitaxelloaded poly(lactide)-tocopheryl polyethylene glycol succinate nanoparticles. Biomaterials 2006; 27: 4025-4033.
  • 13. Mansour HM, Rhee YS, Wu X. Nanomedicine in pulmonary delivery. Int J Nanomed 2009; 4: 299-319.
  • 14. Astete CE, Sabliov CM. Synthesis and characterization of PLGA nanoparticles. J Biomat Sci-Polym E 2006; 17: 247-289.
  • 15. Maitani Y, Nakamura A, Tanaka T, Aso Y. Hydration of surfactant-modified and PEGylated cationic cholesterolbased liposomes and corresponding lipoplexes by monitoring a fluorescent probe and the dielectric relaxation time. Int J Pharm 2012; 427: 372-378.
  • 16. Reshetov V, Zorin V, Siupa A, D’Hallewin MA, Guillemin F, Bezdetnaya L. Interaction of liposomal formulations of meta-tetra(hydroxyphenyl)chlorin (Temoporfin) with serum proteins: protein binding and liposome destruction. Photochem Photobiol 2012; 88: 1256-1264.
  • 17. Yang T, Cui FD, Choi MK, Cho JW, Chung SJ, Shim CK, Kim DD. Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation. Int J Pharm 2007; 338: 317-326.
Turkish Journal of Medical Sciences-Cover
  • ISSN: 1300-0144
  • Yayın Aralığı: Yılda 6 Sayı
  • Yayıncı: TÜBİTAK
Arşiv
Sayıdaki Diğer Makaleler

Ameliorating effects of curcumin on nicotine-induced mice testes

Sait POLAT, Şaban DORAN, Gülfidan COŞKUN, Hülya ÖZGÜR

Ali Timuçin ATAYOĞLU, MELTEM SOYLU, SİBEL SİLİCİ, NERİMAN İNANÇ

Hakan YILMAZ, Ali Riza ERTÜRK, Ayşe KARATAŞ, İbrahim Burak ATCI, Alaettin YURT

Mehtap ŞAHİN, Fikriye Figen AYHAN, Pinar BORMAN, Hüseyin ATASOY

Görkem Karakaş UĞURLU, Semra Ulusoy KAYMAK, Mustafa UĞURLU, Sibel ÖRSEL, Ali ÇAYKÖYLÜ

Chenna ZHENG, Huiyong YANG, Qingyao WANG, Huachun RAO, Yong DIAO

FATİH BÜYÜK, Özgür ÇELEBİ, Elif ÇELİK, Bekir ÇELEBİ, Selçuk KILIÇ, Aliye Gülmez SAĞLAM, Doğan AKÇA, Mehmet DOĞANAY, Salih OTLU, Mitat ŞAHİN

Seyit Murat BAYRAM, Gül GÜRSOY, Asli Araz GÜNGÖR, Fatih GÜNGÖR, Eray ATALAY

The role of baseline Ga-68 DOTATATE positron emission tomography/computed tomography in the prediction of response to fixed-dose peptide receptor radionuclide therapy with Lu-177 DOTATATE*

Çiğdem SOYDAL, Ahmet PEKER, Elgin ÖZKAN, Nuriye Özlem KÜÇÜK, Kemal Metin KIR

Mehmet PARLAK, Aytekin ÇIKMAN, Yasemin BAYRAM, Nesrin CEYLAN, Ulaş ÇALIŞIR, Mustafa BERKTAŞ